Literature DB >> 10452509

Medullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease.

S Guyétant1, F Dupre, J C Bigorgne, B Franc, N Dutrieux-Berger, M Lecomte-Houcke, M Patey, B Caillou, G Viennet, O Guerin, J P Saint-Andre.   

Abstract

Thirty-eight patients (25 women, 13 men; mean age, 57.8 [32 to 91]) showing one or more medullary thyroid microcarcinomas (ie, < 1 cm), with no prior MEN II or medullary thyroid carcinoma history in their family, were reviewed. Follow-up was available for 29 patients (mean, 53.6 months [1 to 147]). 21 patients (72.4%) are alive and free of disease, four patients (13.8%) died during follow-up without disease, 2 patients are alive with disease (local recurrence and persistent hypercalcitoninemia) after 80 and 99 months, respectively, and 2 patients died of disease after 24 and 46 months. Most tumors were incidental pathological findings (19 of 38) or were discovered by systematic blood calcitonin measurement for a nodular thyroid disease (15 of 38). Only the four patients who had an unfavorable outcome were symptomatic cases (palpable micro-MTC, diarrhea, cervical lymph node metastasis and pulmonary metastatic disease). The two patients with metastatic disease at diagnosis died during follow-up. In univariate analysis, a symptomatic medullary thyroid carcinoma was a strong predictor of an unfavourable outcome (p < .00008), as were the preoperative calcitonin level (P = .007) and an elevated postoperative calcitonin level (P = .004). Among 30 histopathological criteria, only the presence of amyloid correlated with an unfavorable outcome (P = .018).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452509     DOI: 10.1016/s0046-8177(99)90250-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

2.  Chronic diarrhoea--all in the bowel?

Authors:  S Gupta; C J Tibbs; M J G Farthing; R C G Pollok
Journal:  J R Soc Med       Date:  2007-08       Impact factor: 5.344

3.  Medullary thyroid carcinoma: a 25-year perspective.

Authors:  Xavier Matias-Guiu; Ronald De Lellis
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

4.  Interest of sentinel node biopsy in apparently intrathyroidal medullary thyroid cancer: a pilot study.

Authors:  M Puccini; G Manca; C Ugolini; V Candalise; A Passaretti; J Bernardini; G Boni; P Buccianti
Journal:  J Endocrinol Invest       Date:  2014-06-21       Impact factor: 4.256

Review 5.  C-cell hyperplasia and medullary thyroid microcarcinoma.

Authors:  J A Albores-Saavedra; J E Krueger
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia.

Authors:  G I Uwaifo; A T Remaley; M Stene; J C Reynolds; P M Yen; R H Snider; K L Becker; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

7.  Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta-analysis.

Authors:  Jin Hwa Kim; Jung-Soo Pyo; Won Jin Cho
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

8.  Medullary thyroid carcinoma, follicular variant.

Authors:  Mehtap Cakir; Hasan Altunbas; Mustafa Kemal Balci; Umit Karayalcin; Gulten Karpuzoglu
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases.

Authors:  Lenine G Brandão; Beatriz G Cavalheiro; Consuelo R Junqueira
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

10.  Association of RET codon 691 polymorphism in radiation-induced human thyroid tumours with C-cell hyperplasia in peritumoural tissue.

Authors:  A Bounacer; J A Du Villard; R Wicker; B Caillou; M Schlumberger; A Sarasin; H G Suárez
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.